Last reviewed · How we verify
Adjunct Treatment to Inhibit Renal Drug Excretion
Approved treatments
- Col-Probenecid · Pfizer Inc.
ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Adjunct Treatment to Inhibit Renal Drug Excretion patent landscape — cliff calendar, originator estates, attackable patents
- Adjunct Treatment to Inhibit Renal Drug Excretion treatment landscape brief
- Adjunct Treatment to Inhibit Renal Drug Excretion treatment updates RSS
Frequently asked questions about Adjunct Treatment to Inhibit Renal Drug Excretion
What drugs treat Adjunct Treatment to Inhibit Renal Drug Excretion?
Tracked treatments include Col-Probenecid.
What is the treatment for Adjunct Treatment to Inhibit Renal Drug Excretion?
Standard treatment for Adjunct Treatment to Inhibit Renal Drug Excretion includes Col-Probenecid. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Adjunct Treatment to Inhibit Renal Drug Excretion patent cliff · Adjunct Treatment to Inhibit Renal Drug Excretion CI report
- Treatment: Col-Probenecid · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing